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Abstract: Chronic pain is a major therapeutic problem as the current treatment options are unsatisfactory with low 
efficacy and deleterious side effects. Voltage-gated Ca
2+ channels (VGCCs), which are multi-complex proteins consisting 
of  1,  ,  , and  2  subunits, play an important role in pain signaling. These channels are involved in neurogenic 
inflammation, excitability, and neurotransmitter release in nociceptors. It has been previously shown that N-type VGCCs 
(Cav2.2) are a major pain target. U.S. FDA approval of three Cav2.2 antagonists, gabapentin, pregabalin, and ziconotide, 
for chronic pain underlies the importance of this channel subtype. Also, there has been increasing evidence that L-type 
(Cav1.2) or T-type (Cav3.2) VGCCs may be involved in pain signaling and chronic pain. In order to develop novel pain 
therapeutics and to understand the role of VGCC subtypes, discovering subtype selective VGCC inhibitors or methods 
that selectively target the inhibitor into nociceptors would be essential. This review describes the various VGCC subtype 
inhibitors and the potential of utilizing VGCC subtypes as targets of chronic pain. Development of VGCC subtype 
inhibitors and targeting them into nociceptors will contribute to a better understanding of the roles of VGCC subtypes in 
pain at a spinal level as well as development of a novel class of analgesics for chronic pain. 
Keywords:   2  subunit, Inhibition, L-type Ca
2+ channels, N-type Ca
2+ channels, Pain, Targeting, T-type Ca
2+ channels, 
Voltage-gated Ca
2+ channels.  
1. INTRODUCTION 
  Pain is the somatosensory detection of noxious stimuli, 
helping our body be aware of damaging stimuli. These 
signals are transmitted into the central nervous system 
through a subset of peripheral nerve fibers, which are called 
nociceptors. These consist of thinly myelinated A  and 
unmyelinated C fiber primary sensory neurons [1]. These 
neurons are pseudobipolar as they have two peripheral and 
central branches arising from a single axon coming from the 
cell body. These cell bodies are clustered in dorsal root 
ganglia (DRG). The sizes of the cell bodies of nociceptors 
range from small (100-400  m
2) to medium (400-1200  m
2). 
Generally, large DRG cells are not considered to be 
nociceptive neurons. The presynaptic terminals, which are 
the central branches of nociceptors, form synapses with 
second order neurons in specific locations of the spinal cord. 
For example, A  fibers terminate in lamina I and V, while C 
fibers project to Lamina I and II. Neurotransmitter release in 
the synapse is the primary mode of transmission to the 
central nervous system from nociceptors. Substance P, 
CGRP, and glutamate are representative examples of these 
neurotransmitters. The peripheral nerve endings innervate 
the skin and viscera that receive either the high threshold 
internal (inflammatory soups) or external (heat, acid, and   
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pressure) signals. These nerve endings also release substance 
P and CGRP, which may contribute to neurogenic inflammation 
[2]. 
  Nociceptors are specialized high-threshold neurons that 
respond to noxious stimuli. The peripheral nerve endings of 
nociceptors express specialized high threshold receptors such 
as ligand gated ion channels (TRP channels, P2X channels, 
and ASIC channels, etc) and G-protein coupled receptors 
(Mas-related G-protein class, etc). These proteins convert 
high threshold external or internal stimuli into electrical 
signaling such as action potentials, which are propagated 
through primary sensory neurons. Here, voltage-gated Na
+
channels (Nav1.3, Nav1.7, and Nav1.8), as relay stations, are 
in charge of this action potential propagation. As a final step 
in the peripheral nervous system, the electrical signaling 
ends in presynaptic terminals and transmits to second order 
neurons in the spinal cord. In the presynaptic terminals, 
neuronal voltage-gated Ca
2+ channels (VGCCs, in particular, 
Cav2.2) play an important role in pain neurotransmitter 
release such as CGRP, Substance P, and glutamate. Taken 
together, this series of events (transduction, propagation, and 
transmission) in peripheral nociceptors comprise pain 
signaling. 
  While the pain signaling works as a physiological 
defense system to protect ourselves from harmful conditions, 
persistent tissue and nerve injury cause chronic inflammatory 
and neuropathic pain, which comprise major medical 
problems. Inflammatory pain is caused by tissue injury, 
which release inflammatory mediators containing cytokines 
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and neuropeptides. Neuropathic pain is caused by neural 
damage by HIV infection, cancer, mechanical trauma, and 
spinal cord injury. Dysfunctional pain is defined by pain 
with no identifiable sources. Fibromyalgia, irritable bowel 
syndrome, interstitial cystitis, erythromelalgia, paroxysmal 
extreme pain disorder, and complex regional pain syndrome 
(CRPS) are examples of neuropathic or dysfunctional pain. 
Nociceptive or inflammatory pain can be called adaptive 
because the pain usually disappears after avoidance of 
stimuli or resolution of injury. The neuropathic pain and 
dysfunctional pain are maladaptive, in which pain occurs 
without identifiable and detectable stimuli (spontaneous 
pain) and also with hyperalgesia and allodynia [3]. These 
symptoms are a result of the neuron’s increased sensitivity to 
painful- and normal-threshold stimuli, and hyperexcitability. 
Modulations of ion channels and GPCRs by chronic 
pathological pain are involved in high sensitivity or 
hyperexcitability. 
  A significant amount of progress in understanding 
chronic pain mechanisms has been achieved, although it is 
still not complete due to its complexity and multiple 
mechanisms. Many proteins have been suggested as targets 
for pain therapeutics; however, actual therapeutic targets are 
few in number. The nociceptive and inflammatory pain 
currently are mainly addressed with NSAIDs and opioids 
that inhibit COX enzymes and activate opioids receptors, 
respectively. However, current therapeutics for chronic and 
maladaptive pain are not satisfactory. The major problems of 
current chronic pain medicines are side effects and low 
efficacy [4]. For example, opioids and NSAIDs (e.g. codeine 
and ibuprofen) have several side effects such as tolerance 
and gastric problems, respectively. More importantly, they 
are not considered effective especially against neuropathic 
chronic pain. Number needed to treat (NNT; an 
epidemiological measure of effectiveness) of these drugs is 
around 4 (NNT, 1 is ideal and 2.5 is satisfactory). Other than 
these medications, antidepressants, antiepileptics, topical 
capsaicin, and local anesthetics have been used for chronic 
neuropathic pain, but they still have the same limitations as 
opioids and NSAIDs [5]. With an unmet need for pain 
therapeutics, it is important to pursue the development of 
novel therapeutics with high efficacy and low side effects. 
  Among the targets of chronic pain, inhibiting VGCCs in 
nociceptors is an effective way for reducing pain. As 
mentioned above, VGCCs are directly involved in 
neurotransmitter release at synapses in the spinal cord, as 
well as neurogenic inflammation in the peripheral nerve 
endings. This means that VGCCs for neurons of the 
peripheral nerve system are end points for both transmitting 
pain signals into central nervous system and for evoking 
neurogenic pain in the periphery. In addition, many 
endogenous factors up-regulated by neuropathic pain 
modulate VGCCs to induce hypersensitivity [6]. Currently, 
three drugs targeting VGCCs are commercially available for 
neuropathic pain medication; pregabalin, gabapentin, and 
ziconotide. However, pregabalin and gabapentin have 
serious side effects and low efficacy, and also their role in 
inhibiting VGCCs is controversial. Ziconotide still has 
severe side effects and requires intrathecal administration 
through a catheter and pump. On the positive side, it doesn’t 
lead to tolerance and dependence and is more effective for 
refractory pain than even opioids [7]. In this regard, 
discovering more selective and potent drugs for VGCCs and 
targeting them into nociceptors is beneficial for chronic pain 
therapeutics. The following will describe VGCC subtypes as 
targets of chronic pain, VGCC subtype inhibitors, and the 
possibility of therapeutic application and strategies based on 
the characteristics of VGCCs. 
2. VOLTAGE-GATED CA
2+ CHANNELS 
  Calcium ions (Ca
2+) exist at a higher level of 
concentration outside the cell membrane (~2 mM) than 
inside (~50-100 nM). The Ca
2+ gradient is maintained until 
the activation of VGCCs by membrane depolarization, which 
is evoked by activation of ligand gated ion channels or 
GPCRs. The resulting Ca
2+ influx (10 to 100 times increase 
of intracellular Ca
2+) plays a role in muscle contraction, 
hormone secretion, synaptic transmission, enzyme activity, 
and gene expression in different cell types such as muscle, 
endocrine cells, and neurons [8, 9]. 
  The functional VGCCs are a protein complex of 1, 2,
, and  subunits. The 1 subunits are the key molecule of 
the channel complex because it is capable of Ca
2+
conduction, or generating Ca
2+ influx. The 2, , and 
subunits are auxiliary. They increase the expression of 1
subunits in the plasma membrane as well as modulate the 
function of 1 subunits, resulting in functional diversity in 
different cell types. The 2 subunits increase maximum 
currents by trafficking of the 1 subunits. Also, they increase 
the inactivation rate as well as shift steady state inactivation 
into hyperpolarization. The  subunits located in the cytosol 
also increase maximum currents by enhancing trafficking of 
1 subunits, shifting activation to the left, and increasing 
open probability. However, the role of  subunits as auxiliary 
subunits is controversial. Rather, they are more important in 
modulating AMPA receptors. A recent review described 
other functions of auxiliary subunits of VGCCs [10]. 
 The  1 subunit consists of ~2000 amino acids and four 
repeated domains, each of which is homologous with 
voltage-gated potassium channels (VGPCs). These domains 
are connected with three intracellular loops. In each domain, 
first four transmembrane segments (S1-S4) form the voltage 
sensing domain, while S5, P-loop, and S6 form the pore 
domain (Fig. 1). Based on sequence differences, the mammalian 
1 subunits are currently classified into 10 subtypes. These 
subtypes have different biophysical properties (activation, 
inactivation, conductance, and deactivation), expression 
patterns, and pharmacology (Table 1). 
  L-type VGCCs, first characterized from cardiac muscle, 
include four genes (Cav1.1~1.4). These channels are 
activated at high voltage, thus classified as HVA (high 
voltage activated) Ca
2+ channels. Their half-maximal 
activations are around -20 to 0mV, except for Cav1.3, which 
is activated by low voltages (-30 ~ -20mV). These channels 
are mainly expressed in cardiac and skeletal muscle cells and 
responsible for muscle contraction, hormonal secretion, and 
gene transcription. Dihydropyridine (DHP) antagonized L-
type VGCCs and had been useful for isolating and 
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(PAA) and benzothiazepine (BTZ) have antagonizing effects 
against the channels. 
 P/Q-type  VGCCs  (Cav2.1) were found to be expressed in 
purkinje cells and cerebellar granule neurons, and N-type 
VGCCs (Cav2.2) were characterized from the brain [11]. 
These channels are expressed in presynaptic nerve terminals 
and play an important role in neurotransmitter release. These 
two types have been known to play a complementary role. 
These channels are antagonized by peptide neurotoxins -
Agatoxin IVA and -conotoxin MVIIA, respectively. 
Residual current of R-type VGCCs (Cav2.3) still remains 
after blocking L-, N-, P/Q-type VGCC subtypes. Another 
peptide neurotoxin SNS-482, isolated from the tarantula 
Hysterocrates gigas, inhibits R-type VGCCs. The expression 
of P/Q-type, N-type, and R-type Cav channels are restricted 
to neurons. R-type VGCCs as well as L-type VGCCs (Cav1.3 
only) are activated at rather lower voltage than other 
channels, but still are classified as HVA channels. 
  The other class of VGCCs (Cav3.1~3.3) are LVA (low 
voltage activated) T-type VGCCs. These channels are 
activated with half voltage activation of -46 ~ -44mV, thus 
open at resting membrane potentials. These channels 
regulate pacemaking, subthreshold activation, and repetitive 
firing in cardiac or neuronal cells. Interestingly, T-type 
VGCCs are not modulated by auxiliary subunits such as 2
and  subunits [12, 13]. 
  In addition to subunit associations and subtype 
differences, alternative splicing gives more diversity in the 
function of VGCCs. For example, N-type VGCCs have a 
number of splice variants, which depend on developmental 
stage and cell types [14, 15]. The splicing events are 
regulated by a neuronal splicing factor such as Nova [16]. 
Fig. (1). Primary structure of 1 subunits of VGCCs. 
Table 1.  Classification of Voltage-gated Ca
2+ Channels 
 Current Name Channel Name Gene Name Half Activation Voltage (Reference [23]) 
Cav1.1 CACNA1S 8~14mV 
Cav1.2 CACNA1C -4~-18.8mV 
Cav1.3 CACNA1D -15~-37mV 
L-type
Cav1.4 CACNA1F -2.5~-12mV 
P/Q-type Cav2.1 CACNA1A -5~10mV 
N-type Cav2.2 CACNA1B 7.8~9.7mV 
High-voltage activated 
(HVA)
R-type Cav2.3 CACNA1E -29.1~3.5mV 
Cav3.1 CACNA1G -46mV 
Cav3.2 CACNA1H -46mV 
Low-voltage activated 
(LVA)
T-type
Cav3.3 CACNA1I -44mV Pharmacological Inhibition of Voltage-gated Ca2+ Channels for Chronic  Current Neuropharmacology, 2013, Vol. 11, No. 6    609
For example, Nova-2 increases inclusion of e24a and 
decreases inclusion of e31a of N-type VGCCs in brain [17]. 
These variants showed distinct gating properties such as 
channel activation, inactivation and drug responsiveness. It 
has been shown that e37a of N-type VGCCs are expressed in 
capsaicin sensitive neurons, which are involved in pain 
behaviors. Further, in order to see the specific role of e37a of 
N-type VGCCs, e37a was replaced with e37b in mice. These 
mice showed no differences in pain behaviors, but less 
responsiveness to morphine. This fact suggested that splice 
variants can affect the pharmacology of N-type VGCCs and 
alternative splicing by splicing factors are important for pain 
signaling [18-20]. 
  In generating action potentials, voltage-gated Na
+
channels (VGSCs) and voltage-gated K
+ channels (VGPCs) 
are involved in rising and falling phase. Thus, VGSC blocker 
abolishes action potentials. However, in contrast to VGSC 
blockers, VGCC blockers have shown small effects on 
action potentials. For example, L-type VGCC blockers 
abolish contractile force without a major change in the action 
potentials. Generally, VGCC blockers broaden the falling 
phase of action potentials [21]. However, it has been argued 
that less contribution of L-type VGCC currents in action 
potentials result from slow and use-dependent inhibition of 
L-type VGCC blockers [22]. Notably, T-type VGCCs are 
activated at near resting membrane potentials; therefore, it 
will amplify weak signals and cause low-amplitude intrinsic 
neuronal oscillations. T-type VGCC knockout (Cav3.1-/-) 
shows reduced burst firing in thalamocortical neurons, 
suggesting its contribution to repetitive firing of action 
potentials. Two VGCC subtypes, Cav1.3 and Cav2.3, are 
activated at relatively low voltage so that they may have 
distinct roles with other HVA Ca
2+ channels such as 
spontaneous firing or rhythmic burst discharges [23, 24]. 
These diverse characteristics of each subtype orchestrate 
neuronal spikes in sensory nervous system. 
3. VGCC SUBTYPES AND PAIN 
  The role and importance of each VGCC subtype in pain 
signaling would be firstly glimpsed by where they are 
expressed in pain processing in the DRG and spinal cord. 
Further, the effect of genetic ablation of VGCC subtypes in 
mice on pain behaviors gives invaluable information about 
their function in pain. Also, their roles in chronic pain 
mechanisms, which are related to peripheral and central 
sensitization, would be determined by up- or down- 
regulation by neuropathic and inflammatory pain. It has been 
shown that various subtypes of VGCCs are expressed in 
dorsal root ganglia (DRG) according to their sizes [25]. In 
situ hybridization using RNA probes showed that all 
subtypes of VGCCs are expressed in rat DRG neurons 
except Cav1.4 and Cav3.1. It also has been shown that 21
and  22 subtypes are expressed in small and medium 
neurons (possibly nociceptors), while 23 subtype is 
expressed in large neurons [26]. VGCC subtypes are also 
expressed in the spinal cord, suggesting critical roles in pain 
signaling through second order neurons in the spinal cord 
[27, 28]. In presynaptic nerve terminal of DRG and 
postsynaptic cells in spinal cord, VGCCs play different roles. 
VGCC subtypes in presynaptic terminals are involved in 
neurotransmitter release and excitability; those in the spinal 
cord are involved in excitability and central sensitization 
[29]. In peripheral nerve endings, it has been suggested that 
VGCC subtypes play an important role in peptide release, 
which might be involved in neurogenic inflammation [2]. 
Several reviews have already described the importance of 
VGCC subtypes in terms of pain signaling [30, 31]; this 
review focuses on the particular roles of VGCC subtypes 
based on recent evidence on their localization, genetic 
ablation, and regulation upon chronic pain. 
3.1. L-type Ca
2+ Channels 
  L-type VGCCs are broadly expressed in skeletal and 
cardiac muscle, neurons, auditory hair cells, pancreatic cells, 
and retina [32]. Several lines of evidence have shown that 
DRG and spinal cord neurons express Cav1.2 and Cav1.3  
[33, 34]. Electrophysiology in DRG showed that L-type 
VGCCs are present largely in small and large neurons [25]. 
Whether these channels are regulated in chronic pain state is 
not conclusive. One study using RT-PCR showed that L- 
type VGCCs are down-regulated in DRG upon chronic 
constriction injury (CCI) and sciatic nerve axotomy in rats 
[35]. They suggested that decreases of Cav1.2 and Cav1.3 in 
DRG contribute to hyperexcitability of neuropathic pain by 
modulating Ca
2+-dependent inactivation or facilitation as a 
negative feedback [36]. Inversely, it has been shown that 
Cav1.2 is up-regulated in the spinal cord in the sciatic nerve 
ligation (SNL) model. In this study, it has also been shown 
that knockdown of Cav1.2 using siRNA and peptide nucleic 
acids (PNA) reversed the neuropathic pain, while that of 
Cav1.3 did not [37]. This fact suggests that spinal Cav1.2 is 
important in pain signaling. It was supported by miR-103 
decreasing translational levels of Cav1.2. Neuropathic pain 
decreases miR-103 and thus increases Cav1.2, resulting in 
hyperexcitability and allodynia [38]. Cav1.3 rather is 
involved in other sensory modalities or motor neurons 
according to its expression in lamina IX in spinal cord [39]. 
Knockout mice of Cav1.3 did not display atypical pain 
behaviors. The lack of effects in Cav1.3-/- mice might result 
from compensation effects, but the fact that RNAi 
knockdown of Cav1.3 did not affect pain behavior supports 
diminished role of Cav1.3 to pain signaling [40, 34]. Overall, 
although Cav1.3 is expressed in the spinal cord and brain 
stem, it seems to have fewer effects on pain signaling. 
However, it could not be ruled out because rather low 
voltage activation of Cav1.3 might contribute to spontaneous 
neuronal firing similar with T-type VGCCs. Another 
interesting aspect of L-type VGCCs in pain processing is 
their expression in peripheral nerve endings. Ca
2+ influxes in 
corneal nerve terminals branching A- and C-fibers are 
inhibited by nifedipine and diltiazem [2]. This result 
suggests that L-type VGCCs also are involved in 
neuropeptide release in peripheral nerve endings, which 
contribute to neurogenic inflammation. 
3.2. P/Q-type Ca
2+ Channels 
  P/Q-type VGCCs are more centrally expressed than 
peripherally, thus being more associated with migraine. 
Missense mutations of P/Q-type VGCCs cause familial 
hemiplegic migraine (FHM) [41]. It has been known that 
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VGCCs in the central nervous system. For example, these 
two channels mediate neurotransmitter release in distinct 
hippocampal inhibitory neurons [42]. Also, in DRG neurons, 
Cav2.1 is not localized with substance P or CGRP, which 
showed similar localization with Cav2.2. -agatoxin IVA, a 
P/Q-type VGCC blocker, did not affect the release of 
substance P or CGRP [27, 43]. In the spinal cord, they are 
located in presynaptic nerve terminals of lamina II-VI, while 
Cav2.2 is in the presynapse of lamina I and II. Therefore,   
it is likely that P/Q-type VGCCs are more involved in 
polysynaptic transmission rather than monosynaptic 
transmission between nociceptors and lamina I and II [29]. 
-agatoxin TK, a P/Q-type VGCC blocker, had no effect on 
postsynaptic Ca
2+ influx in lamina I [29]. However, we 
cannot rule out the possibility of relevance to chronic pain, 
because a recent report showed that induction of spinal LTP, 
a marker of chronic pain, was strongly suppressed with -
agatoxin IVA [44]. 
  In accordance with its expression, the effects of Cav2.1 in 
pain signaling are rather complicated. In SNL neuropathic 
pain model, -agatoxin IVA has little effect on pain 
behaviors [45-47]. In knockout mice for Cav2.1, mice show 
enhanced sensitivity to thermal stimuli. Also, two P/Q-type 
VGCC mutant mice Leaner mice (tgla/tgla) and Roller mice 
(tgrol/tgrol) have been examined for pain behaviors. Leaner 
mice (tgla/tgla) showed reduced mechanical pain but 
enhanced heat pain like knockout mice. However, Roller 
mice (tgrol/tgrol) showed reduced sensitivity to heat pain in 
a gene concentration-dependent manner [48-50]. These facts 
suggest that the role of P/Q-type VGCCs in pain is 
complicated and is involved in different sensory modalities 
compared to N-type VGCCs. Therefore, the role of P/Q-type 
VGCCs in pain should be interpreted in specific contexts, as 
another review suggested [30]. 
3.3. N-type Ca
2+ Channels 
 Cav2.2 is expressed in the central and peripheral nervous 
systems including the brain, spinal cord, and primary sensory 
neurons [51, 27]. It has been reported that Cav2.2 and 
substance P expression overlapped in DRG and the spinal 
cord. In accordance with their location, Cav2.2 antagonists 
-conotoxins MVIIA and GVIA block neurotransmitter 
release in the spinal cord [43, 52-54]. Autoradiography   
of -conotoxins also show that Cav2.2 is rich in laminae I 
and II [55, 56]. However, contrary to suggested specific 
localization of Cav2.2 with substance P, electrophysiology in 
DRG shows that N-type VGCC current are present evenly 
regardless of the size [25, 57]. In terms of regulation, it has 
been shown that the expressions of Cav2.2 are modulated   
by inflammatory and neuropathic pain. For example, 
inflammation by intraplantar CFA increases N-type VGCC 
protein expression but not mRNA [58]. CCI model, a 
neuropathic pain model, showed increased immunoreactivity 
against Cav2.2 in lamina II in spinal dorsal horn [59]. 
However, partial sciatic nerve injury (PSNL) did not regulate 
Cav2.2 but rather up-regulate the 2 subunit [60]. 
Inflammation by intraplantar CFA reduced the contribution 
of N-type VGCCs in NK1 positive neuron in lamina I [61]. 
Therefore, up-regulation of 1 subunit of Cav2.2 by 
inflammation and nerve injury is ambiguous. Rather, 
increase of Cav2.2 depends on 2 subunit, which traffic 
Cav2.2 into cell membranes because mRNA of Cav2.2 has 
not been changed upon inflammatory pain [58]. Also, it is 
possible that 2 subunit cause synaptogenesis so that 
increase of synaptic area affects upregulation of Cav2.2 [62]. 
  Genetic ablation of Cav2.2 also confirmed its importance 
on chronic pain. Three groups independently generated 
Cav2.2-/- mice and examined for pain behaviors [63-65]. 
Their results in acute pain are not consistent with each other. 
Kim et al. showed a reduction in mechanical acute pain but 
not thermal acute pain [64]. However, in two other groups, 
knockout mice only showed a reduction in thermal acute 
pain. In accordance with this inconsistence on acute pain, -
conotoxins’ effect on acute pain are conflicting [66-69]. 
However, in formalin test, all knockout mice showed 
delayed responses in phase II, suggesting N-type VGCCs are 
involved in inflammatory pain. Also, intrathecal -
conotoxins potently block pain behaviors by neuropathic 
pain [45]. These results suggest antagonizing Cav2.2 is more 
beneficial in reducing pathological pain than acute pain, 
although the molecular basis of these differential effects 
remains elusive. 
3.4. R-type Ca
2+ Channels 
 HVA  Ca
2+ currents resistant to L-, P/Q-, and N-type 
VGCC blockers are R-type VGCC currents, which are 
generated by Cav2.3. The channel subtype is also expressed 
in DRG and the spinal cord. Like Cav2.2, there has been a 
report that Cav2.3 has several, at least six, isoforms. Among 
them, Cav2.3(e) is expressed in small, IB4 negative, and 
capsaicin positive DRG cells, suggesting this isoform is 
potentially involved in pain signaling [70, 71]. In fact, SNX-
482, an antagonist for R-type VGCCs, reduced hyperexcitability 
of C- and A- fibers in SNL neuropathic pain models [72, 
73]. In terms of regulation, it has been shown that R-type 
VGCC currents was reduced by neuropathic pain models 
such as PSNL, while N-type VGCC currents was increased, 
suggesting adaptive changes into N-type VGCCs. However, 
interestingly, Cav2.3-/- mice showed the adaptive changes 
into L-type VGCCs, suggesting a role of R-type VGCCs in 
adaptive mechanisms by neuropathic pain [74]. This might 
explain why Cav2.3-/- mice showed normal behavior against 
acute pain [75, 76]. Also, there is a report that R-type 
VGCCs are expressed in PAG (periaqueductal gray) and has 
an anti-nociceptive role. These results show that, like P/Q-
type VGCCs, the contribution of R-type VGCCs to pain is 
rather complicated. 
3.5. T-type Ca
2+ Channels 
  T-type VGCCs are broadly expressed in heart, muscle, 
brain, and peripheral nerve, suggesting its contribution to 
cardiac function, epileptics, sleep, and pain. In the pain 
signaling, T-type VGCCs (Cav3.2 and Cav3.3) also are 
expressed in small and medium DRG and spinal cord, being 
involved in excitability, neurotransmitter release, and pain 
sensitization. It has been reported that presynaptic Cav3.2 
was involved in glutamate release in synapse of lamina I and 
II [77, 78]. In particular, spinal T-type VGCC currents was 
important in hyperalgesia in NK receptors positive lamina I 
neurons, emphasizing their role in central sensitization [79]. Pharmacological Inhibition of Voltage-gated Ca2+ Channels for Chronic  Current Neuropharmacology, 2013, Vol. 11, No. 6    611
In terms of regulation, it has been shown that T-type VGCC 
currents are down-regulated by neuropathic pain condition 
such as the CCI model. Control mice showed 25% T-type 
VGCC current in medium sized DRG cells but these were 
abolished in the neuropathic pain model [80, 81]. However, 
more recently, it has been shown that T-type VGCC current 
is increased in small neurons of CCI neuropathy model and 
also that Cav3.2 and Cav3.3 mRNA is increased in rat 
chronic compression of DRG (CCD) model [82, 83]. The 
different regulations of T-type channels in small and medium 
sized DRG cells and their physiological effects should be 
further investigated. Possibly, medium sized DRG cells do 
not participate in pain circuitry. Shin et al. showed that 
Cav3.2 is involved in D-hair receptors. Cav3.2-/- mice 
showed no effects on mechanistic nociceptive C-fibers [84]. 
Despite the promiscuous role of T-type channels, other 
evidences indicated that Cav3.2 is involved in specific 
contexts of pain such as visceral pain and diabetic 
neuropathic pain. For example, butyrate, which is increased 
by irritable bowel syndrome, up-regulated T-type VGCC 
currents and antisense knockdown of Cav3.2 reversed the 
hypersensitivity [85]. Selective T-type VGCC blocker, 
(3,5,17)-17-hydroxyestrane-3-carbonitrile, reduced 
thermal and mechanical allodynia from diabetic neuropathy 
in leptin deficient mice [86]. Silencing of Cav3.2 using 
antisense oligodeoxynucleotides also reduced hyperalgesia 
and allodynia of rat CCI model [87]. Further, antisense for 
Cav3.2 and Cav3.3 attenuated pain in CCD model [88]. In 
accordance with these knock down experiment, Cav3.2 
knockout mice showed attenuation in pain behaviors [89]. 
Interestingly, there was a report that genetic ablation of 
Cav3.1 causes hypersensitivity to noxious visceral stimuli, 
which is involved in a lack of thalamic burst firing [90]. 
However, we cannot exclude the possibility of Cav 3.1 
involvement in neuropathic pain such as the SNL model 
[91]. Taken together, among LVA VGCCs, peripheral 
Cav3.2 is an extremely prominent target for analgesic 
development. 
3.6.  2  Subunits 
2 subunits increase Ca
2+ current amplitude by 
increasing functional 1 subunits at membrane site [92]. 
Therefore,  2 subunits have been used to increase Ca
2+
currents in functional assay for VGCCs [93]. Also, these 
subunits modulate gating kinetics and pharmacology of 1
subunits. These biophysical characteristics might affect 
hyperexcitability by neuropathic pain [94]. The importance 
of 2 subunits in chronic pain has been verified that the 
subunits are up-regulated by neuropathic and inflammatory 
pain [95]. For example, inflammation by intraplantar CFA 
increases mRNA and protein expression of 2 subunits 
[58]. It has been shown that mRNA levels of 21 are 
upregulated particularly in small DRG of PNSL models [96]. 
In addition, the relevance of 2 subunits in pain is 
supported by interesting evidence that 2 subunit homolog 
straightjacket is also responsible for thermal pain in 
Drosophila [97]. In accordance with this result, 23 mutant 
mice showed increased latency on thermal pain [97]. 
Recently, another mechanism of 2 has been revealed that 
the  2 subunit is responsible for synaptogenesis by 
interaction with thrombospondins [62]. This fact suggests 
that the synaptogenesis by 2 subunit might affect 
hyperexcitability and chronic pain. 
  It has been known that gabapentinoids such as gabapentin 
and pregabalin alleviate neuropathic pain by reducing Ca
2+
current. However, the direct inhibiting effects for VGCCs 
are controversial. Several report in the literature reported that 
gabapentin inhibited high-threshold Ca
2+ current by acting 
on 2 subunits [98-100]. However, other evidences showed 
that these drugs did not show VGCC current blocking effects 
[92]. More likely, gabapentin may reduce excitability by 
inhibiting synaptogenesis. The exact mechanism of 2 in 
chronic pain remains elusive. 
4. VGCC INHIBITORS 
  Three VGCC subtypes (Cav1.2, Cav2.2, and Cav3.2) play 
an important role in either DRG or the spinal cord in pain 
processing and chronic pain development. Given that these 
1 subunits are 24-multiple transmembrane domains, it is no 
wonder that various extracellular ligands (either exogenous 
or endogenous) and intracellular modulators interact with 
VGCCs and modulate functions of VGCC subtypes, thus 
resulting in regulation of chronic pain phenotypes. These 
regulators can be used for therapeutic developments for 
pathological pain. For example, -conotoxin MVIIA, which 
extracellularly interacts with N-type VGCCs, has been 
approved by U.S. FDA for refractory pain. A tat-associated 
peptide CRMP-2, which intracellularly interferes with the 
interaction between N-type VGCCs and collapsin (a synaptic 
protein enhancing the function of N-type Cav currents), 
showed analgesic effects [101]. These inhibitors were quite 
useful for pain therapeutic developments and strategy for 
targeting these into nociceptors. 
4.1. L-type Ca
2+ Channel Inhibitors 
  It has been well established that classic calcium channel 
blockers DHP, PAA, and BTZ mainly target L-type VGCCs. 
Nifedipine, verapamil, and diltiazem are representative 
calcium channel blockers, respectively (Fig. 2A) [102]. 
These has been called “Ca
2+ antagonist” because they are 
neutralized with elevated Ca
2+ concentration [103]. These 
drugs have been known to bind to pore forming regions (S5 
or S6 in domain III and IV, Fig. 1). For example, isradipine 
(DHP) and devapamil (PAA) interact with S6 in domain IV 
[104]. Nitrendipine (DHP) binds to S5-S6 of domain III 
[105]. Diltiazem (BTZ) also binds to S5 and S6 in domain  
III and IV [106]. It has been known that the binding site of 
DHP is close to the extracellular surface based on   
the blocking effects of extracellular and intracellular 
application of charged DHP [107]. DTZ323, a quaternary 
1,5-benzothiazepine analog, inhibited current extracelluarly, 
but not intracellulary, showing that BTZ also interacts with 
the extracellular portion of Ca
2+ channels. However, D890, 
quaternary form of methoxyverapamil, only inhibited Ca
2+
current intracellularly, showing that binding site of PAA can 
be accessed inside of the cells. It should be noted that 
voltage-gated ion channels are moving targets which show 
conformational changes between closed, open, inactivated 
states. Some drugs showed different affinities against 
different state of channels. This phenomenon is called “state-
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“frequency dependency” [108]. The state or use dependency 
of the drug is useful in terms of therapeutic developments 
because neuropathic pain is usually related to hyper- 
excitability. It has been shown that nitrendipine binds the 
inactivate state of cardiac calcium channels with subnanomolar 
affinity but the resting state with ~700nM affinity [109]. 
Other than these small molecules, conotoxin TxVII blocks 
L-type VGCCs. Interestingly, TxVII inhibits DHP sensitive 
currents in cultured Lymnaea RPeD1 neurons, but not in 
PC12 cells, suggesting that how it has subtype selectivity 
[110]. However, there is still no information which subtype 
is involved in the action of TxVII and it might modulate pain 
signaling. 
  As many authors mentioned, analgesic effects of L-type 
Cav blockers are ambiguous. Ca
2+ channel blockers, 
including nifedipine, verapamil, and diltiazem had no effects 
on pain behaviors when injected intrathecally [111, 73]. 
However, intraperitoneal injection of verapamil reduced 
mechanical and thermal pain in rats. Also, intrathecal 
verapamil and flunarizine reduced thermal pain in an opioid 
receptor dependent manner [112, 113]. In the neuropathic 
pain model of SNL, nicardipine reduced pain behaviors [37]. 
It is probable that these blockers act on L-type VGCCs in 
both excitatory and inhibitory neurons in the spinal cord, 
showing sum effects of the blockers. Also, different affinities 
of blockers against Cav1.2 and Cav1.3 might explain the 
inconsistency of in vivo analgesic activities. Therefore, 
subtype specific blockers against Cav1.2 or the specific 
targeting of drugs into nociceptors might improve the 
analgesic effect of L-type VGCC blockers because of the 
preferential expression of Cav1.2 in nociceptor and its pain 
modulation. 
4.2. N-type Ca
2+ Channel Inhibitors 
  In contrast to the organic blockers for L-type VGCCs, 
peptide neurotoxins from cone snails have been used for 
isolation and characterization of N-type VGCCs. -
conotoxins GVIA and MVIIA isolated from the venom of 
Conus geographus and Conus magus, respectively, block N-
type VGCCs with nanomolar affinity (Fig. 2B). Electro- 
physiology using chimeric channels has shown that -
conotoxin GVIA bind to S5 and H5 in domain III [114]. 
Binding sites of -conotoxins GVIA and MVIIA are 
partially overlapped, which suggest they have similar 
Fig. (2). Molecular structures of VGCC subtype blockers (A) L-type VGCC blockers (B) N-type VGCC blockers (C) T-type VGCC 
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binding mechanisms [115]. Due to their high specificity and 
nanomolar range affinity, they have been useful to 
characterize the function of N-type VGCCs in physiology. 
Eventually, synthetic -conotoxin MVIIA was approved by 
U.S. FDA in 2004 for refractory pain. Since confirming N-
type VGCCs as a pain therapeutic target, many academics 
and companies have developed other peptide neurotoxins 
and active small molecules. The main reason of this is that 
the use of ziconotide has been limited due to uncomfortable 
intrathecal administration, severe side effects, and cost of 
production [116]. A good example is -conotoxin CVID 
isolated from Conus catus, which now is in clinical trials as 
Leconotide. This conotoxin has been improved in terms of 
selectivity for N-type over P/Q-type VGCCs. In behavioral 
tests, intrathecal -conotoxin CVID has a better therapeutic 
index in pain animal studies [69]. Surprisingly, a recent 
report showed that intravenously administered Leconotide 
has an analgesic effect without side effects [117]. This could 
circumvent the need for the uncomfortable intrathecal 
administration of Ziconotide. Another -conotoxin FVIA, 
isolated from Conus fulmen, has a better reversibility 
compared to -conotoxin MVIIA, which might improve side 
effects and managements of ziconotide administration. 
Several spider toxins also showed improvements in terms of 
their effects on motor coordination. The examples are 
huwentoxin-I and PnTx3-6, which showed low motor 
deficits [118, 119]. However, all these peptide neurotoxins 
are still expensive to produce due to limited peptide 
synthesis and then low cysteine folding yield. 
  As for small molecules against Cav2.2, Takashi et al. 
described current developments of N-type VGCC blockers 
[120]. Several groups tried to develop small molecules based 
on a structural analysis of -conotoxin MVIIA or GVIA. 
Other groups tried to design and synthesize blockers based 
on pre-existing organic blockers. Currently, the developed 
small molecules have several moieties such as piperazine, 4-
aminopiperidine, aryl sulfonamide, and aryl heterocycle 
moiety. The snutch group designed and synthesized two N-
type VGCC blockers NP078585 and NP118809 to favor 
selectivity over L-type VGCCs. The chemical structures are 
based on a structure-activity relationship of flunarizine and 
lomerizine. NP118809 has been favored for further 
development due to low off-target activity to hERG Kv 
channels that mediate cardiac action potentials. Currently, it 
has been developed as Z160 (previously, NMED-160 or 
MK-6721) and is in phase IIa study by Zalicus (Fig. 2A). 
Methoxy groups adjacent to benzoyl linker of NP078585, 
which has trimethoxybenzyl piperazine moiety from 
flunarizine and lomerizine, are substituted with S-Me group, 
resulting in a high potency for N-type VGCCs [121, 122]. 
Merck designed and synthesized aminopiperidine sulfonamide 
inhibitors, which are state-dependent blockers. These 
compounds inhibit CFA-induced inflammatory pain and SNL 
neuropathic pain in a Cav2.2 expression-dependent manner 
[123]. TROX-1 was also discovered by Merck (Fig. 2A). An 
IC50 of this compound in a depolarized state is 400 nM in rat 
DRG, but in a hyperpolarized state is 2.6  M, showing a 
characteristic of state dependent blockers. Oral 10mg/kg 
TROX-1 showed analgesic effects in inflammatory and 
neuropathic pain similarly with NSAIDs and pregabalin 
[124, 125]. Ono Pharmaceutical designed and synthesized L-
cysteine based N-type VGCC blockers (Fig. 2A). Oral 
administration of this compound (30mg/kg) showed 
analgesic effects in the rat formalin test and CCI neuropathic 
pain, but high dose (100mg/kg) did not have an effect on 
cardiac or motor function [126, 127]. 
4.3. T-type Ca
2+ Channel Inhibitors 
  Mibefradil (Ro 40-5967), a tetralol derivative, was 
developed as an anti-anginal and anti-ischemic agent   
(Fig. 2C) [128, 129]. However, it was withdrawn by Roche 
due to its interaction with liver enzyme [130]. In spite of   
the withdrawal, it has been used for research due to its 
selectivity for T-type VGCCs. Intraperitoneal injection of 
mibefradil reduced mechanical and thermal pain [131]. In rat 
neuropathic pain model (SNL), intraplanar and intraperitoneal 
mibefradil showed dose dependent effects on mechanical 
and thermal allodynia, but intrathecal injection did not show 
any effect [132]. In contrast to this, intrathecal mibefradil 
decreased neuropathic pain by CCD models [83]. These data 
suggested the involvement of T-type VGCCs in acute and 
neuropathic pain. Interestingly, intraperitoneal mibefradil 
enhances antinociceptive effects of opioids and blocks its 
tolerance but not dependence, although its mechanism is not 
clear [133]. Intraperitoneal ethosuximide, another T-type 
VGCC blocker, showed lower efficacy than mibefradil 
[132]. Intrathecal ethosuximide also showed dose dependent 
inhibition of neuropathic pain by SNL and spinal 
hyperexcitability [134]. Intraperitoneal ethosuximide had 
analgesic effects on chemotherapy induced pain, which is 
resistant to opioids and MK801, an NMDA antagonist [135]. 
  Inspired by analgesic effects with mibefradil and 
ethosuximide, many academic labs and companies have tried 
to find selective and potent T-type VGCC blockers [136]. 
One achievement is TTA-A2 synthesized by Merck (Fig. 
2C). This compound blocked recombinant T-type VGCCs 
with an IC50 of 10~90 nM at more depolarized voltages   
(-75~-80mV, large fraction of channels in inactivated state), 
while with an IC50 of 4~22  M at hyperpolarized voltages  
(-100~-110mV) in heterologous T-type VGCC expressed in 
HEK cells and native T-type VGCCs [137, 138]. This 
evidence showed use dependency of TTA-A2, which is 
useful for reducing hyperexcitability related to chronic pain 
[137, 138]. The analgesic effects of oral TTA-A2 were 
examined on acute pain and an irritable bowel syndrome 
model, which is butyrate-induced hypersensitivity. TTA-A2 
inhibited both type of pain but did not reduce acute pain in 
Cav3.2 knockout mice. However, oral administration of 
TTA-A2 disturbs sleep in normal mice but not double 
knockout of Cav3.1 and Cav3.3, indicating possible side 
effects. TTA-A2 inhibited presynaptic T-type VGCCs in the 
superficial laminae of dorsal horn, only affecting excitatory 
synaptic transmission [77]. Merck also developed quinazolinone 
T-type VGCC blocker TTA-Q4, which showed synergetic 
effects with TTA-A2 [139]. A novel compound has been 
identified through high throughput screening to block Cav3.1 
and Cav3.3 with 20~60 nM affinities. Their developments 
focused on epilepsy, but targeting this into the peripheral 
nervous system would be beneficial (Fig. 2C) [140, 141]. 
Recently, A803467, a blocker of TTX resistant Nav1.8, has 
been examined on T-type VGCCs due to structural similarity 
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of ~5 M at a holding potential of -110mV and interestingly 
stabilized slow inactivated state of hCav3.2 (not Cav3.1 and 
Cav3.3) [142]. Therefore, analgesic mechanism of A803467 
might partially result from T-type VGCC inhibition. 
  Zonisamide, 1,2-benzisoxazole-3-methanesulfonamide, is 
known as an anticonvulsant and inhibitor of repetitive firing, 
thus it is proposed as a T-type VGCC blocker [143]. It also 
was involved in central poststroke pain [144]. In a recent 
electrophysiological study, a high dose (2mM) of zonisamide 
partially inhibited Cav3.2 current with 30% block and did not 
show use-dependent block [145]. Trazodone, a treatment for 
insomnia and depression, also blocked heterogeneous T-type 
VGCC current with an IC50 of 23~45 M. Butamben, a local 
anesthetic, also inhibits T-type VGCC currents with an IC50 
of 200 M in addition to N-type VGCCs. Interestingly, it 
accelerates T-type VGCC kinetics [146]. It has been shown 
that trimethadione, as a T-type VGCC blocker, inhibited 
hyperalgesia in a dose dependent manner. However, it does 
not inhibit LVA current in somatosensory thalamic neurons 
[147, 148]. 
  It should be noted that many endogenous molecules 
modulate T-type VGCCs in addition to the small molecules 
described above. For example, it has been reported that the 
endogenous lipid NAGly (N-arachidonoyl glycine) or 
NAGABA-OH inhibited T-type VGCC currents with a 
preference to Cav3.2 by stabilizing inactivated state based on 
the observation of hyperpolarized shift in the steady-state 
inactivation [149]. These lipids blocked recombinant Cav3.2 
with EC50 of ~600nM and ~200nM, respectively, and 
showed selectivity over the cannabinoid receptor or TRPV1. 
In behavior tests using Cav3.2-/- mice, these lipoamino acids 
showed thermal analgesia in a Cav3.2-dependent manner. 
Other endogenous modulators of T-type VGCCs are 5 
reduced neuroactive steroids [150, 151]. These endogenous 
molecules have potential to be developed into analgesics. 
  Another family of inhibitors modulating T-type VGCCs 
is peptides or protein neurotoxins produced by the venom 
organ of venomous animals such as spiders, scorpions, sea 
anemones, and cone snails. The founding member of T-type 
VGCC blocking toxin is kurtoxin, isolated from the venom 
of the scorpion Parabuthus transvaalicus [152]. It was 
reported that kurtoxin blocks Cav3.1. However, it turned out 
to block other HVA channels as well as Cav3.1 and Cav3.3 
[153]. More recently, it has been reported that ProTx-I 
preferentially block Cav3.1 over Cav3.2 by a interaction with 
the putative voltage sensing domain (S3-S4 linker in domain 
IV) of hCav3.1 [154]. Three-dimensional structures of 
kurtoxin and ProTx-1 have been determined by nuclear 
magnetic resonance. Ensuing structural studies will provide 
invaluable pharmacopore information similar to what was 
shown for the N-type VGCC blocker ziconotide [155]. 
5. PROSPECTS 
  VGCC subtype inhibitors including ziconotide (-
conotoxin MVIIA) showed both potential and limitations as 
chronic pain therapeutics. Several strategies for overcoming 
the limitations have been implemented to enhance the 
inhibitor specificity for voltage-gated ion channels (either 
small molecule or peptide), some of which were already 
applied to VGCC subtypes. These include silencing 
nociceptors, a development of use-dependent blockers, and 
expression of tethered peptide neurotoxins. 
5.1. Silencing Nociceptor 
 Binshtok  et al. reported an interesting approach to 
overcome low specificity of a local anesthetic lidocaine 
[156]. Although the strategy targeted VGSCs, it deserves 
consideration as a potential application to VGCCs. Lidocaine 
(pKa 7.8) has more portions of lipid soluble forms, which 
can penetrate the cell membrane to reach its binding site. 
QX-314 (low pKa), first synthesized by the Astra 
Phamaceutical Company in the early 1970s, is a quaternary 
ammonium derivative of lidocaine. It is a permanently 
charged form and cannot permeate the membrane. Thus, it 
has been known to have a binding sidedness that only by 
internal application of QX-314 it reach its binding site. 
Binshtok et al. recognized that large molecule such as QX-
314 can pass through the pore of activated TRPV1, which is 
expressed specifically in nociceptors. Therefore, nociceptor-
specific internalization of QX-314 has been achieved 
through co-application of QX-314 and capsaicin, a ligand for 
TRPV1. Internalized QX-314 specifically blocked animal 
pain behaviors for several hours without any sensory or 
motor deficits. However, external QX-314 alone did not 
block sodium current. Internalization of QX-314 by 
capsaicin in the cells has been verified by tandem mass 
spectroscopy and electrophysiology [157, 158]. It is very 
meaningful that the specificity of VGSC blocker QX-314 is 
achieved by the localization of TRPV1, although previously 
QX-314 was only considered a research tool. In the same 
way, if small molecules for VGCCs have internal binding 
sidedness, this strategy should be considered. While 
targeting VGSCs result in inhibiting action potential 
generation for propagation of pain signaling, targeting 
VGCCs in nociceptors may be even more effective by 
blocking both synaptic transmission in presynaptic nerve 
terminals as well as peptide release in peripheral nerve 
ending. 
  There have been several studies that characterize the 
sidedness of permanently charged organic calcium 
antagonists. For example, the effect of charged DHP 
(amlodipine and SDZ 207-180) on L-type VGCC currents 
has been examined internally by electrophysiology. 
However, the internally applied charged DHP did not show 
any blocking effect, meaning DHP is not appropriate for this 
strategy [107, 159]. However, D-890 (N-methyl-verapamil) 
is active only when inside the cells so it might be a good 
option for this silencing strategy using TRPV1 channel 
[160]. It would be interesting if the recently discovered N-
type and T-type VGCC blockers can be used in this strategy. 
5.2. High Throughput Screening for Searching use 
Dependent Blockers 
  As described above, VGCCs are moving targets and thus 
several blockers can preferentially bind to the inactivated 
state; a common characteristics of hyperexcitable cells [161]. 
It has been suggested that ziconotide is a state-independent 
drug, which might influence side effects. Several academic 
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drugs for VGCCs. One way to discover use dependent   
drugs for VGCCs is via  high throughput Ca
2+ imaging 
experiments. Detection of intracellular Ca
2+ influx using 
fluorescence dyes is a well-established readout of the 
function of VGCC subtypes [162]. Therefore, screening 
VGCC subtypes are relatively easy compared to other VGSC 
or VGPC subtypes. For high throughput screening, cell lines 
heterologously expressing VGCC subtypes is frequently 
used. However, typical cell lines (e.g. HEK cells) for 
screening have rather high membrane potentials. For 
example, HEK293 cell lines have a resting membrane 
potentials at -12mV, which inactivates most of the VGCC 
subtypes [163]. To overcome this, inward rectifier K
+
channels are co-transfected with VGCC subtypes. After 
transfecting the K
+ channels, the membrane potentials can  
be controlled with potassium concentrations for a use-
dependent assay. One group used 4 mM and 14 mM KCl as 
baseline buffers, which represent resting and inactivated 
states of VGCC subtypes, respectively. They then used a 
high concentration of KCl (e.g. 80mM) to induce 
depolarization [125]. This high throughput assay was 
complemented by an automated patch clamp assay, which 
achieves accuracy before they conducted manual patch 
clamp [164]. Differently from HVA VGCC subtypes, 
screening for T-type VGCCs seems rather difficult because 
of the existence of a large portion of inactivated channels 
even at resting membrane potentials. Two groups already 
reported a T-type VGCC assay with co-transfection of T-
type VGCCs and Kir2.2 [165, 166]. Another group used   
an interesting approach to use gramicidin to remove 
inactivation [167]. These improvements of methodologies 
for high throughput screening will help the identification of 
VGCC subtype blockers, some of which will show use-
dependent activity. 
5.3. Tethered Peptide Neurotoxin and Gene Therapy 
  Peptide neurotoxins are another large class of ion channel 
blockers. These toxins have a high proportion of cysteines in 
their sequences, which form multiple disulfide bonds and 
thus contribute to rigid structural integrity. These toxins have 
been isolated from the venom of cone snails, spiders, 
scorpions, snakes, and sea anemones. This means that 
peptide neurotoxins are encoded by genes and modifiable by 
genetic engineering. Interestingly, several endogenous 
cysteine-rich peptides or proteins also modulate voltage-
gated ion channels. For example, lynx1 is a glycosyl- 
phosphatidylinositol (GPI) anchored protein which has 10 
cysteines and modulates nicotinic acetylcholine receptors 
[168]. CKAMP-44 also has 8 cysteines and modulates 
AMPA receptors [169]. This protein has a transmembrane 
domain so that they are also membrane-tethered. Inspired by 
GPI anchored lynx1, Ibañez-Tallon et al. showed that 
peptide neurotoxins tethered by GPI has a blocking effect on 
7 nicotinic acetylcholine receptor in Zebrafish, which could 
overcome for the problems of genetic ablation of ion 
channels such as compensation [170]. Tethered spider toxins 
targeting VGSCs are also expressed in Drosophila to affect 
circadian rhythm. Peptide neurotoxins blocking VGCC 
subtypes also have been tested in mice. Tethered fluorescent 
peptide neurotoxins, -conotoxin MVIIA and -Aga IVA 
inhibiting Cav2.2 and Cav2.1, respectively, have been 
delivered through lenti virus to show a reduction in chronic 
pain [171]. 
  Tethered peptide neurotoxins can be used for two 
purposes. One is for novel peptide neurotoxin screenings to 
identify their function. A large set of peptide neurotoxin 
genes have been characterized without identification of their 
respective functions. It is difficult to characterize their 
functions one by one through peptide neurotoxin synthesis 
and functional assay. It is relatively easier to use model 
animals such as Drosophila and C. elegans, which have well 
documented behaviors. This approach will accelerate 
identifying peptide blockers for VGCC subtypes. The other 
purpose is to use tethered peptide neurotoxins for gene 
therapy. Potentially, the tethered -conotoxin MVIIA can be 
targeted into specific cells (eventually nociceptors) by virus 
targeting [172]. Although safety concerns still remain to be 
considered, as gene therapy has only recently been approved 
in Europe, gene therapy using tethered peptides can be a 
promising way to treat neuropathic pain [173]. 
6. CONCLUSION 
  Pain therapeutics for chronic pain still have unmet need 
because current therapy is unsatisfactory mainly due to low 
efficacy or high side effects. Considering the important roles 
of VGCC subtypes in neurotransmitter release, excitability, 
and neurogenic inflammation, VGCC subtypes (Cav1.2, 
Cav2.2, Cav3.2, and 2) in nociceptors are promising targets 
for chronic pain. Many VGCC subtype blockers that have 
been developed have contributed to chronic pain therapeutics 
and understanding the role of VGCC subtypes. Known and 
novel VGCC blockers (or identified by improved high 
throughput screening methods) can be targeted into 
nociceptor improve medication for chronic pain in terms of 
high efficacy and safety.  
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